Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks
Clinical-stage biopharmaceutical company Sionna Therapeutics Inc. (NASDAQ: SION ) announced topline clinical trial results from two nucleotide binding domain 1 (NBD1) stabilizer candidate programs targeting cystic fibrosis (CF). The findings indicated that its PreciSION CF Phase 2a trial assessing SION-719 missed its k